Co-Diagnostics Advances Flu/RSV Test Toward FDA Clearance and Names New CSO

summarizeSummary

Co-Diagnostics submitted an FDA 510(k) for its Flu/RSV test and appointed a new CSO, while reporting a $6.3M quarterly loss and $3.6M cash balance.

check_boxKey Events · Earnings and Guidance · CODX

• FDA 510(k) Submission

  Submitted 510(k) premarket notification with concurrent CLIA Waiver by Application for Co-Dx PCR Flu A/B & RSV test on Co-Dx PCR Pro instrument.

• New Chief Scientific Officer

  Appointed Wes Lindsey, Ph.D., MBA, as CSO to lead scientific and regulatory strategy, including FDA submissions.

• Q2 Financial Results

  Net loss of $6.3 million ($1.46 per share) on revenue of $0.17 million; cash and equivalents of $3.6 million as of June 30, 2026.

• International Clinical Progress

  Initiated clinical performance studies in India for CoSara PCR MTB test; advanced Bundibugyo virus assay development.

auto_awesomeAnalysis · CODX · Industrial Applications And Services

The second quarter brought a net loss of $6.3 million and a cash position of just $3.6 million, but the more consequential development is the FDA 510(k) submission for the Co-Dx PCR Flu A/B & RSV test on the Co-Dx PCR Pro instrument, accompanied by a concurrent CLIA Waiver by Application. This represents a pivotal regulatory step toward commercializing the company's point-of-care molecular diagnostics platform. To steer scientific and regulatory strategy, including FDA submissions, the company appointed Wes Lindsey, Ph.D., MBA, as Chief Scientific Officer. Clinical studies for its tuberculosis test also commenced in India. With a going concern warning and critical cash burn, these regulatory and operational moves are essential for the company's survival and future revenue generation.